Juventas CAR-T LBCL Launch Marks Second Indication
Juventas Cell Therapy Ltd announced the commercial launch of inaticabtagene autoleucel for relapsed or refractory...
Market launch
Kelun-Biotech’s Trastuzumab Botidotin HER2 ADC Launches in China After Phase 3 Win vs T-DM1
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced the official China launch of trastuzumab botidotin,...
Johnson & Johnson Launches ETHICON 4000 3D Laparoscopic Stapler in China
Johnson & Johnson (J&J, NYSE: JNJ) announced today the commercial rollout of its ETHICON 4000 laparoscopic stapler...
Ipsen Launches BYLVAY in China for Rare Liver Disease
France‑based Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced the official commercial launch of its rare‑disease...
AstraZeneca Launches Ultomiris in China for gMG and NMOSD Treatments
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has announced the launch of Ultomiris (ravulizumab), a...
Simcere Launches Quviviq, New Insomnia Therapy in China
Jiangsu Simcere Pharmaceutical Co., Ltd. (HKG: 2096) announced the nationwide launch of its first prescription...
Fosun Launches Futuoning, First‑In‑Class CDK4/6 Inhibitor for HR‑Positive Breast Cancer
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196, SHA: 600196) announced the nationwide launch of...
Santen Launches Tapcom, Preservative‑Free Glaucoma Combo in China
Japan‑based Santen Pharmaceutical Co., Ltd. (TYO: 4536) announced the commercial launch of Tapcom (tafluprost/timolol maleate) in...
Eisai & Biogen Launch Lecanemab in Austria & Germany – First Cause‑Based Alzheimer’s Therapy
Japan-based Eisai (TYO: 4523) and US-based Biogen (NASDAQ: BIIB) have officially launched Lecanemab (LEQEMBI)—the first...
Pfizer’s Emblaveo Prescribed in Shanghai Hospitals for First Time Nationwide
US giant Pfizer Inc. (NYSE: PFE) announced that its Emblaveo (aztreonam and avibactam) has been...
MSD Officially Launches Zerbaxa in China to Tackle Drug-Resistant Infections
US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) announced on August 13, 2025, the...
Novartis Begins Shipping Next-Gen Anti-VEGF Drug Beovu for Diabetic Macular Edema
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced on August 11, 2025, the initiation of commercial...
Johnson & Johnson MedTech Launches VARIPULSE Platform for Atrial Fibrillation in Asia-Pacific
US major Johnson & Johnson MedTech announced the launch of its VARIPULSE Platform in the...
HutchMed Announces First Commercial Shipments of Tazverik Across China
China-based HutchMed (NASDAQ: HCM, HKG: 0013) announced the first commercial shipments of Tazverik (tazemetostat) across...
CANbridge’s Geruining Approved for Gaucher Disease Treatment: First Domestically Developed ERT
China-based CANbridge Pharmaceuticals Inc., (HKG: 1228) announced that the first prescription of its Geruining (velaglucerase...
Platinum Life Biotech’s Ruibosheng First Prescribed in China for aGVHD Treatment
Beijing-based Platinum Life Biotech’s Ruibosheng (amimestrocel) has been first prescribed in China, following conditional marketing...
AstraZeneca Launches Truqap in China for PIK3CA/AKT1/PTEN-Altered Breast Cancer
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) announced the official commercial launch of Truqap (capivasertib) in...
Eisai’s Urece Arrives in Shanghai, Poised for Chinese Market Entry
Eisai’s (TYO: 4523) China unit announced that the first batch of its innovative drug Urece...
Sanofi to Ship Beyfortus Ahead of RSV Season, Ensuring Global Availability
France-based Sanofi (NASDAQ: SNY) announced plans to commence shipments of Beyfortus (nirsevimab) in early Q3...
Biogen Launches Qalsody in China for SOD1-ALS Treatment
US-based Biogen (NASDAQ: BIIB) officially launched Qalsody (tofersen) in China this week. The drug, the...